Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 8:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Methylphenidate-extended release Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

NCT00178503
View directory record Official record
Conditions
Autism, Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate-extended release, Methylphenidate-immediate release, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

NCT01239030
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Methylphenidate Hydrochloride Extended Release Capsules, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
6 Years to 18 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
Little Rock, Arkansas • Irvine, California • National City, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 2 Interventional Results available

Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits

NCT01399827
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Interventions
ADHD Medication, Omega-3 Fatty Acids
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 4 Interventional Results available

A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.

NCT03811847
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Methylphenidate Extended Release Oral Capsule, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 95 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 4 Interventional Results available

A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00564954
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dex-methylphenidate hydrochloride extended-release (Focalin XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
5
States / cities
Little Rock, Arkansas • Winter Park, Florida • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

NCT02520388
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Newport Beach, California • Bradenton, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 2 Interventional

Testing the Effects of Methylphenidate on Multiple Sclerosis

NCT02286557
View directory record Official record
Conditions
Fatigue in Multiple Sclerosis
Interventions
Methelphenidate, Placebo
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 4 Interventional Results available

Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)

NCT00889915
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate transdermal system, Lisdexamfetamine dimesylate, Osmotic-release oral system methylphenidate (OROS MPH), Mixed amphetamine salts extended release
Drug
Lead sponsor
Duke University
Other
Eligibility
6 Years to 17 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 4 Interventional

Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy

NCT00323947
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Epilepsy
Interventions
Extended Release Methylphenidate (OROS-Methylphenidate)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CTx-1301 Comparative Bioavailability Study

NCT04138498
View directory record Official record
Conditions
ADHD
Interventions
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 3 Interventional Results available

Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth

NCT01109849
View directory record Official record
Conditions
ADHD, Growth
Interventions
behavior therapy, Extended release (ER) methylphenidate product, monitoring, drug holiday, caloric supplement
Behavioral · Drug · Other + 1 more
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

NCT01338818
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Ritalin LA (methylphenidate hydrochloride extended release)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 3 Interventional Results available

Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR

NCT00393042
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dexmethylphenidate, Mixed Amphetamine Salts, ER, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Chicago, Illinois • Northbrook, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 26, 2026, 8:52 PM EDT
Not listed Phase 4 Interventional

A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD

NCT02677519
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Aptensio XR
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 6 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 1 Interventional Results available

General Anesthesia Emergence Induced by Methylphenidate

NCT02327195
View directory record Official record
Conditions
Delayed Emergence From Anesthesia
Interventions
Methylphenidate HCl, Placebo
Drug
Lead sponsor
Nicoleta Stoicea
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 26, 2026, 8:52 PM EDT
Recruiting Phase 4 Interventional

Treating Young Children With Attention Deficit Hyperactivity Disorder

NCT07300956
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Guanfacine (GUA), Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 5 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 26, 2026, 8:52 PM EDT
Recruiting Phase 4 Interventional

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

NCT06577779
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Methylphenidate Hydrochloride Extended Release Capsule
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 26, 2026, 8:52 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD

NCT02638168
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Behavioral Insomnia of Childhood
Interventions
Immediate Release Methylphenidate, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years to 12 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers

NCT00901576
View directory record Official record
Conditions
Healthy
Interventions
SPD503, Concerta, SPD503 + Concerta
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

NCT00776009
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 26, 2026, 8:52 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

NCT04987762
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Adhansia XR
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
4 Years to 12 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Colorado Springs, Colorado • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 3 Interventional Results available

NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01835548
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
NT0102, Placebo
Drug
Lead sponsor
Neos Therapeutics, Inc
Industry
Eligibility
6 Years to 12 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 26, 2026, 8:52 PM EDT
Completed Phase 2 Interventional Results available

Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00409708
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2011 · Synced Oct 26, 2026, 8:52 PM EDT